Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant LDRT + Tislelizumab + Afatinib in HNSCC
NCT06804850Phase 2Withdrawn
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab, afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Planned start Jan 2025; status: withdrawn.
02
Drugs
tislelizumabafatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06804850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804850.